Results 121 to 130 of about 17,612,218 (346)

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation [PDF]

, 1994
Steven G. Gourlay, Andrew Forbes, Tracey Marriner, D. Pethica, John J. McNeil   +4 more
openalex   +1 more source

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Outcome for West Syndrome Following Surgical Treatment [PDF]

, 1991
Basim M. Uthman, S.A. Reid, B. J. Wilder, Mary R. Andriola, Ahmad Beydoun   +4 more
openalex   +1 more source

Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement

European Respiratory Journal, 2018
J. van Ingen, T. Aksamit, C. Andrejak, E. Böttger, E. Cambau, C. Daley, D. Griffith, L. Guglielmetti, S. Holland, G. Huitt, W. Koh, C. Lange, P. Leitman, T. Marras, K. Morimoto, K. Olivier, M. Santin, J. Stout, R. Thomson, E. Tortoli, R. Wallace, K. Winthrop, D. Wagner   +22 more
semanticscholar   +1 more source

Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry

Molecular Oncology, EarlyView.
Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson, Emma L. Dorward, Kristyn Jurrius, Nathalie Nataren, Markus Tondl, Kay K. Myo Min, Michaelia P. Cockshell, Anahita Fouladzadeh, John Toubia, Mark DeNichilo, Delphine Merino, Claudine S. Bonder   +11 more
wiley   +1 more source

Efficacy of endoscopic sinus surgery in the treatment of chronic rhinosinusitis

International Archives of Otorhinolaryngology, 2010
Introduction: The endoscopic sinus surgery (FESS) is currently regarded as the gold standard in the treatment of chronic rhinosinusitis (RNSC), with or without nasal polyposis refractory to medical therapy optimized.
Basílio, Flávia Machado Alves, Arantes, Murilo Carlini, Ballin, Annelyse Cristine, Dallagnol, Moises Rafael, Bornhausen, Mathias Bohn, Szkudlarek, Denilson Cavazzani, Santos, Marco César Jorge, Mocellin, Marcos   +7 more
doaj  

Treatment of cytomegalovirus retinitis with zidovudine and ganciclovir in patients with AIDS: outcome and toxicity. [PDF]

, 1990
Ann Millar, Robert F. Miller, Gary Patou, Adrian Mindel, R J Marsh, S.J.G. Semple   +5 more
openalex   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

TREATMENT OUTCOME OF PULMONARY TUBERCULOSIS UNDER OBSERVATIONAL THERAPY: AT DISTRICT SWAT, KPK, PAKISTAN

, 1969
Shah Jehan, Mir Sadiq Shah, Rahmat Ali Khan, Khurshid Ahmad, Saira Naeem   +4 more
openalex   +2 more sources